

5-Bromopyrimidin-2(1H)-one

H. S. Yathirajan,^a B. Narayana,^b
B. V. Ashalatha,^b B. K. Sarojini^c
and Michael Bolte^{d*}

^aDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India, ^bDepartment of Chemistry, Mangalore University, Mangalagangotri 574 199, India, ^cDepartment of Chemistry, P. A. College of Engineering, Nadupadavu, Mangalore 574 153, India, and ^dInstitut für Anorganische Chemie, J. W. Goethe-Universität Frankfurt, Max-von-Laue-Strasse 7, 60438 Frankfurt/Main, Germany

Correspondence e-mail:
bolte@chemie.uni-frankfurt.de

Key indicators


Single-crystal X-ray study
 $T = 173$ K
Mean $\sigma(\text{C}-\text{C}) = 0.007$ Å
 R factor = 0.036
 wR factor = 0.092
Data-to-parameter ratio = 12.6

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

The geometric parameters of the title compound, $\text{C}_4\text{H}_3\text{BrN}_2\text{O}$, are in the usual ranges. The crystal packing is characterized by $\text{N}-\text{H}\cdots\text{N}$ and $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds and short $\text{O}\cdots\text{Br}$ contacts.

Comment

Pyrimidine and its derivatives are biologically important components of nucleic acids (DNA, RNA) and coenzymes. They can be the parent compound of many drugs, including the barbiturates. Over the years, the pyrimidine system has proved to be an important pharmacophore, interacting with the synthesis and functions of nucleic acids or the HIV drug zidovudine (Logoja, 2005). 5-Bromopyrimidine is used as an intermediate for the synthesis of pharmaceuticals, especially for sulfa drugs and disinfectants. Because the purines, pyrimidines and pteridines are widely distributed in natural materials and living organisms, it is not surprising that so many derivatives of these compounds have biological activity, but the range of activity reaches beyond analogues and anti-metabolite action and it seems that, in some cases, the heterocyclic ring acts as a useful carrier for biologically active substituents (Hurst, 1980).



A perspective view of the title compound, (I), is shown in Fig. 1. Bond lengths and angles can be regarded as normal (Cambridge Structural Database, Version 5.28, November 2006; Allen, 2002; *Mogul* Version 1.1; Bruno et al., 2004).

The crystal packing shows zigzag chains of hydrogen-bonded molecules (Fig. 2) running along the vector $[101]$. The molecules in a chain are held together by $\text{N}-\text{H}\cdots\text{N}$ and $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds. Two parallel chains are further connected by $\text{O}\cdots\text{Br}$ contacts [$\text{O}1\cdots\text{Br}1^{\text{ii}} = 2.895(3)^\circ$, $\text{C}1-\text{O}1\cdots\text{Br}1^{\text{ii}} = 162.9(3)^\circ$ and $\text{O}1\cdots\text{Br}1^{\text{ii}}-\text{C}4^{\text{ii}} = 177.68(16)^\circ$; symmetry code: (ii) $-x + \frac{1}{2}, y + \frac{1}{2}, -z + \frac{3}{2}$].

It is remarkable that compound (I) is not isostructural with either 5-chloro-pyrimidin-2-one (Furberg & Solbakk, 1974) or 5-fluoro-pyrimidin-2-one (Furberg & Petersen, 1972).

Experimental

The title compound was prepared according to the literature procedure of Langerman (1951) and X-ray quality crystals were obtained

Received 18 January 2007

Accepted 19 January 2007

by slow evaporation of a solution in acetone (m.p. 523 K). Analysis (%) for $C_4H_3BrN_2O$: found (calculated): C 27.32 (27.46), H 1.61 (1.73), N 15.92 (16.01).

Crystal data

$C_4H_3BrN_2O$
 $M_r = 174.99$
 Monoclinic, $P2_1/n$
 $a = 3.9481(6) \text{ \AA}$
 $b = 17.383(2) \text{ \AA}$
 $c = 7.7968(11) \text{ \AA}$
 $\beta = 102.461(12)^\circ$
 $V = 522.49(12) \text{ \AA}^3$

$Z = 4$
 $D_x = 2.225 \text{ Mg m}^{-3}$
 Mo $K\alpha$ radiation
 $\mu = 7.75 \text{ mm}^{-1}$
 $T = 173(2) \text{ K}$
 Block, colourless
 $0.32 \times 0.30 \times 0.27 \text{ mm}$

Data collection

Stoe IPDS II two-circle diffractometer
 ω scans
 Absorption correction: multi-scan (MULABS; Spek, 2003; Blessing, 1995)
 $T_{\min} = 0.111, T_{\max} = 0.129$

3791 measured reflections
 982 independent reflections
 868 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.067$
 $\theta_{\text{max}} = 25.6^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.036$
 $wR(F^2) = 0.092$
 $S = 1.12$
 982 reflections
 78 parameters
 H atoms treated by a mixture of independent and constrained refinement

$w = 1/[\sigma^2(F_o^2) + (0.05P)^2 + 0.2707P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.80 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.74 \text{ e \AA}^{-3}$
 Extinction correction: SHELXL97 (Sheldrick, 1997)
 Extinction coefficient: 0.030 (3)

Table 1

Hydrogen-bond geometry ($\text{\AA}, ^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N2-H2\cdots N6^i$	0.84 (6)	2.00 (6)	2.829 (6)	167 (5)
$C3-H3\cdots O1^i$	0.95	2.52	3.229 (6)	132

Symmetry code: (i) $x - \frac{1}{2}, -y + \frac{3}{2}, z + \frac{1}{2}$.

H atoms were found in a difference map, but those bonded to C atoms were refined using a riding model, with $C-H = 0.95 \text{ \AA}$ and $U_{\text{iso}}(H) = 1.2U_{\text{eq}}(C)$. The H atom bonded to N was refined freely.

Data collection: X-AREA (Stoe & Cie, 2001); cell refinement: X-AREA; data reduction: X-AREA; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: PLATON (Spek, 2003) and XP in SHELXTL-Plus (Sheldrick, 1991); software used to prepare material for publication: SHELXL97.

References

Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
 Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.




Figure 1

The molecular structure of compound (I), with the atom-numbering scheme. Displacement ellipsoids are drawn at the 50% probability level.




Figure 2

A packing diagram for (I). Hydrogen bonds are shown as dashed lines and $O\cdots Br$ contacts as dotted lines.

Bruno, I. J., Cole, J. C., Kessler, M., Luo Jie, Motherwell, W. D. S., Purkis, L. H., Smith, B. R., Taylor, R., Cooper, R. I., Harris, S. E. & Orpen, A. G. (2004). *J. Chem. Inf. Comput. Sci.* **44**, 2133–2144.
 Furberg, S. & Petersen, C. S. (1972). *Acta Chem. Scand.* **26**, 760–768.
 Furberg, S. & Solbakk, J. (1974). *Acta Chem. Scand. A*, **28**, 435–438.
 Hurst, D.T. (1980). *An Introduction to the Chemistry and Biochemistry of Pyrimidines, Purines and Pteridines*. Chichester, New York, Brisbane and Toronto: John Wiley.
 Langerman, M. J. (1951). *J. Am. Chem. Soc.* **73**, 3011–3012.
 Logoja, I. M. (2005). *Chem. Biodivers.* **2**, 1–50.
 Sheldrick, G. M. (1991). *SHELXTL-Plus*. Release 4.1. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
 Stoe & Cie (2001). *X-AREA*. Stoe & Cie, Darmstadt, Germany.